Two new p73 splice variants, γ and δ, with different transcriptional activity

Journal of Experimental Medicine

Volumn 188, Issue 9, 1998, Pages 1763-1768

  De Laurenzi, Vincenzo ^a   Costanzo, Antonio ^b   Barcaroli, Daniela ^a   Terrinoni, Alessandro ^a   Falco, Mirella ^b   Annicchiarico Petruzzelli, Margherita ^a   Levrero, Massimo ^b   Melino, Gerry ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Apoptosis; Cancer; Differentiation; p53; p73

Indexed keywords

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CANCER; CELL DIFFERENTIATION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA SPLICING; TUMOR CELL; TUMOR SUPPRESSOR GENE;

EID: 0032476743     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.9.1763     Document Type: Article

References (28)

1. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88:323-331.
2. Ko, L.J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054-1072.
3. Nigro, J.M., S.J. Baker, A.C. Preisinger, J.M. Jessup, R. Hostetter, K. Cleary, S.H. Bigner, N. Davidson, S. Baylin, P. Devilee, et al. 1989. Mutations in the p53 gene occur in diverse human tumour types. Nature. 342:705-708.
4. Hollstein, M., D. Sidransky, and C.C. Vogelstein. 1991. p53 mutations in human cancers. Science. 253:49-53.
5. Kaghad, M., H. Bonnet, A. Yang, L. Creancier, J. Biscan, A. Valent, A. Minty, P. Chalon, J. Lelias, X. Dumont, et al. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90:809-819.
6. Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 62:671-680.
7. Choisy-Rossi, C., and E. Yonish-Rouach. 1998. Apoptosis and the cell cycle: the p53 connection. Cell Death Differ. 5: 129-131.
8. el-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817-825.
9. Crook, T., N.J. Marston, E.A. Sara, and K.H. Vousden. 1994. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell. 79:817-827.
10. Kastan, M.B., Q.M. Zhan, W.S. el-Deiry, F. Carrier, T. Jacks, W.V. Walsh, B.S. Plunkett, B. Vogelstein, and A.J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:587-597.
11. Santhanam, U., A. Ray, and P.B. Sehgal. 1991. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. USA. 88:7605-7609.
12. Ragimov, N., A. Krauskopf, N. Navot, V. Rotter, M. Oren, and Y. Aloni. 1993. Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene. 8:1183-1193.
13. Jost, C.A., M.C. Marin, and W.G. Kaelin, Jr. 1997. p73 is a human p53 related protein that can induce apoptosis. Nature. 389:191-194.
14. Brodeur, G.M., G. Sekhon, and M.N. Goldstein. 1977. Chromosomal aberrations in human neuroblastomas. Cancer. 40:2256-2263.
15. Sozzi, G., M.G. Bertoglio, S. Pilotti, F. Rilke, M.A. Pierotti, and G. Della Porta. 1988. Cytogenetic studies in primary and metastatic neuroendocrine Merkel cell carcinoma. Cancer Genet. Cytogenet. 30:151-158.
16. Nomoto, S., N. Haruki, M. Kondo, H. Konishi, T. Takahashi, T. Takahashi, and T. Takahashi. 1998. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res. 58: 1380-1383.
17. Takahashi, H., S. Ichimiya, Y. Nimura, M. Watanabe, M. Furusato, S. Wakui, R. Yatani, S. Aizawa, and A. Nakagawara. 1998. Mutation, allelotyping, and transcription analysis of the p73 gene in prostatic carcinoma. Cancer Res. 58: 2076-2077.
18. Oren, M. 1997. Lonely no more: p73 finds its kin in a tumor suppressor haven. Cell. 90:829-832.
19. Natoli, G., A. Costanzo, F. Moretti, M. Fulco, C. Balsano, and M. Levrero. 1997. Tumor necrosis factor (TNF) receptor signaling downstream of TNF receptor-associated factor 2. J. Biol. Chem. 272:26079-26082.
20. Takeuchi, M., M. Rothe, and D.V. Goeddel. 1996. Anatomy of TRAF2. J. Biol. Chem. 271:19935-19942.
21. Chirillo, P., S. Pagano, G. Natoli, P.L. Puri, V.L. Burgio, C. Balsano, and M. Levrero. 1997. The hepatitis B virus X gene induces p53-mediated programmed cell death. Proc. Natl. Acad. Sci. USA. 94:8162-8167.
22. Lane, D.P., and S. Benchimol. 1990. p53: oncogene or anti-oncogene? Genes Dev. 2:1-8.
23. Clurman, B., and M. Groudine. 1997. Killer in search of a motive. Nature. 389:122-123.
24. Avantaggiati, M.L., V. Ogryzko, K. Gardner, A. Giordano, A.S. Levine, and K. Kelly. 1997. Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 89:1175-1184.
25. Gu, W., X.L. Shi, and R.G. Roeder. 1997. Synergistic activation of transcription by CBP and p53. Nature. 387:819-823.
26. Lill, N., S.R. Grossman, D. Ginsberg, J. De Caprio, and D.M. Livingston. 1997. Binding and modulation of p53 by p300/CBP coactivators. Nature. 387:823-827.
27. Montano, X. 1997. p53 associates with trk tyrosine kinase. Oncogene. 15:245-256.
28. Donehower, L.A., M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery, J.S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:215-221.